Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4514461 | 0.98 | TSHR (0.47) | TSHRNPSR1SIRT1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3878664 | 0.98 | TSHR (0.47) | TSHRNPSR1SIRT1SLC6A2SLC6A4 | |
| SCHEMBL4512714 | 0.88 | TSHR (0.44) | TSHRNPSR1SIRT1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4517854 | 0.87 | TSHR (0.47) | TSHRNPSR1SIRT1SLC6A2SLC6A4 | |
| SCHEMBL29866456 | 0.78 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL42951 | 0.78 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL16303077 | 0.78 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL6192741 | 0.77 | — | — | |
| SCHEMBL5727050 | 0.77 | DRD1 (0.33) | SLC6A2SLC6A4MAPT | |
| Hydrochloric Acid SCHEMBL15569335 | 0.76 | TSHR (0.73) | TSHRNPSR1SLC6A2SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| EP-2007729-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-31 | — | — | EP | claimed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | claimed |
| US-5919795-A | ATHEROSCLEROSIS THERAPY | PFIZER INC. (US) | 1999-07-06 | — | — | US | claimed |
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | disclosed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | disclosed |
| EP-2007729-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | disclosed |
| EP-1837332-A1 | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-26 | — | — | EP | disclosed |
| EP-1806149-A1 | SOLID MEDICINAL PREPARATION IMPROVED IN SOLUBILITY AND STABILITY AND PROCESS FOR PRODUCING THE SAME | Japan Tobacco, Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-6147214-A | Process and intermediates for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide | PFIZER INC (US) | 2000-11-14 | — | — | US | disclosed |
| CN-1252792-A | Process and intermediates for the preparation of 4'-trifluoromethyl-bipheyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide | PFIZER (US) | 2000-05-10 | — | — | CN | disclosed |
| EP-0975598-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 4'-TRIFLUOROMETHYL-BIPHENYL-2-CARBOXYLIC ACID (1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-YL)-AMIDE | PFIZER INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5919795-A | ATHEROSCLEROSIS THERAPY | PFIZER INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998047875-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 4'-TRIFLUOROMETHYL-BIPHENYL-2-CARBOXYLIC ACID (1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-YL)-AMIDE | PFIZER INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | TSHR 846/4885NPSR1 156/4885SIRT1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.